Company intelligence / Profile preview
Axonyx
New York, New York, United Statesaxonyx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Axonyx was a U.S.-based biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system disorders such as Alzheimer’s disease and mild cognitive impairment. Its lead assets included phenserine (Phase III), posiphen (Phase I), and bisnorcymserine/BNC (preclinical). The company licensed core intellectual property from New York University and NIH/NIA, maintained collaborations with these institutions, but did not have commercial products or manufacturing capabilities before being acquired by TorreyPines Therapeutics via a reverse merger completed in October 2006. The combined entity continued under the TorreyPines brand.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Axonyx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axonyx.